Inovio Pharmaceuticals, Inc. filed an 8-K on November 17, 2026, disclosing the appointment of Jeffrey Libson to its Board of Directors effective November 13, 2026, expanding the board from eight to nine members.
Key Highlights
- Board expansion: The Board increased its size from eight to nine directors to create the seat filled by Libson.
- Appointment date: Jeffrey Libson's appointment as director and Finance Committee member became effective November 13, 2026.
- Term: Libson will hold office until the Company's 2027 annual meeting of stockholders, or until his earlier death, resignation, or removal.
- Annual retainers: Libson will receive a $45,000 annual cash retainer for Board service and an additional $5,000 annual cash retainer for Finance Committee service, prorated per program terms.
- Prior advisory role: Libson has served as a mentor and strategic advisor to Inovio since January 2025.
- Legal background: Libson was a partner at Cooley LLP from December 2016 to January 2025, where he was a member of its Global Life Sciences Leadership Team.
Inovio Adds Life Sciences Attorney Jeffrey Libson to Board and Finance Committee
According to the filing, Inovio Pharmaceuticals (NASDAQ:INO) reported that its Board of Directors voted to increase its size from eight to nine directors and appointed Jeffrey Libson, age 72, to fill the newly created seat. Both actions took effect on November 13, 2026. Libson was simultaneously appointed to the Company's Finance Committee.
The filing describes Libson's professional background as centering on life sciences law and advisory work. He served as a partner at Cooley LLP and a member of its Global Life Sciences Leadership Team from December 2016 to January 2025. Before that, the filing states, he was a partner and head of the life sciences practice at Pepper Hamilton LLP from August 1981 to December 2016. From September 2006 to January 2025, he also served as an adjunct professor at The Wharton School of the University of Pennsylvania, teaching a graduate-level course in life sciences entrepreneurship. He holds a BA in Economics and English from Oberlin College and a J.D. from the Duke University School of Law.
Under the Company's Non-Employee Director Compensation Program, the filing disclosed that Libson will receive an annual cash retainer of $45,000 for Board service and an additional $5,000 annual cash retainer for Finance Committee service, both payable and prorated in accordance with program terms. The filing also noted that Libson will receive equity awards in the future under that same program. The filing stated there are no family relationships between Libson and any executive officers or directors, and no arrangements with any other person related to his appointment.
What Was Disclosed
Inovio's 8-K reported the Board's expansion from eight to nine members and the appointment of Jeffrey Libson as director and Finance Committee member effective November 13, 2026, along with the cash retainer terms and his professional background.


Please wait processing your request...